A new form of opioid withdrawal medication called yemkemi, developed in Sweden, could be on the market by next year.
The drug, called yeminig, was developed by a team led by Dr. Olaf Jansson and is meant to help women with chronic pain who are struggling with opioid use and withdrawal.
Dr. Jansson says it could be the most important pain reliever on the planet.
“This drug is meant for women who have suffered with pain for a long time and they have severe and chronic pain and need relief,” he told Ars.
“This drug helps relieve that pain.”
The drug is already available in Sweden and the U.K., and is expected to be approved in 2018, according to a statement from Yeminig.
The company has also been working with the U, U.S. and other countries to create the drug, which is currently undergoing testing.
Yeminigan’s first batch of the drug will be given out in early 2019, and will be available in Europe by the end of 2020.
The treatment, called Yeminikine, has been approved by the European Medicines Agency (EMA), the European Food Safety Authority (EFSA) and the World Health Organization (WHO).
“This is the first time that we have been able to obtain FDA approval for this type of opioid treatment in Europe,” Jansson said.
Yemkemia is also approved for use in Germany and is being developed there by another team.
The German drug company Doktor Pharmaceuticals is also developing the drug.
In the U: Yeminigi is also being developed in the United States, and is scheduled to be on shelves in mid-2020.
This will be the first new opioid medication approved in the U., according to Jansson.
In Canada: Yemikine is also under development in the Canadian province of Quebec, which also has some of the world’s highest opioid rates.
The medication will be licensed to Canadian patients by mid-2021, and has received the green light from Health Canada.
“Yeminikina is a unique medication that will significantly improve the quality of life for women with pain,” said a statement by Health Canada, which has been in talks with Yeminiec to produce the drug there.
Yemi has a low toxicity profile, meaning it doesn’t have addictive properties, and its safety is well documented.
“We’re very excited about the potential for Yemi and we are already working with a number of countries to evaluate the product,” said Dr. Peter Dombrovskis, chairman of the Canadian Pharmaceutical Advisory Committee.
“I can’t wait to see what the results of this will be, and I hope Yemini will become a reality for Canadians.”
Yeminine is not the first opioid to be developed using Yeminiga.
In 2018, a German company called Bodega Pharma developed a painkiller that is supposed to treat chronic pain from chronic pain management.
The product, called Nocen, is currently being evaluated by the FDA.
Nocin is currently under development for use by women with fibromyalgia, a condition in which pain often goes away after some time.
The Nocine painkiller is a generic drug that has been sold under the brand name Opana for more than five years, according of Medscape.com.
“The FDA approved Nocens in late 2018,” said Jansson, who added that the company is now working with European governments to get the approval to market.
“There are a lot of different countries looking at the potential of this drug, and we have many opportunities for that,” he said.
“A lot of people have said that this drug could be a breakthrough, and this is why I think this is an exciting time for this technology.”